Intravenous pulse therapy for tough juvenile arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests whether a type of intravenous medicine (called pulse therapy) can help children with arthritis that hasn't improved after other treatments. It aims to bring the disease into remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child's arthritis is still active despite trying at least two different disease-modifying medicines (DMARDs).
- Your child does not have other connective tissue diseases (like lupus or scleroderma).
- Your child does not have an endocrine disorder, such as a thyroid problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a high-dose steroid injection can help people with rheumatoid arthritis that hasn't improved with other treatments. If you have RA that's not well controlled, this may be an option for you.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Hear when a new Refractory Juvenile Idiopathic Arthritis (Despite 2 DMARDs Still Active) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.